Quantinno Capital Management LP Purchases New Position in PROCEPT BioRobotics Corporation $PRCT

Quantinno Capital Management LP acquired a new position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in the 1st quarter, HoldingsChannel.com reports. The fund acquired 67,700 shares of the company’s stock, valued at approximately $1,693,000.

A number of other hedge funds have also bought and sold shares of the business. Caitong International Asset Management Co. Ltd lifted its position in shares of PROCEPT BioRobotics by 436.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after acquiring an additional 746 shares in the last quarter. Center for Financial Planning Inc. purchased a new position in shares of PROCEPT BioRobotics in the fourth quarter valued at $40,000. US Bancorp DE grew its position in shares of PROCEPT BioRobotics by 175.7% in the third quarter. US Bancorp DE now owns 1,693 shares of the company’s stock valued at $60,000 after purchasing an additional 1,079 shares in the last quarter. Cache Advisors LLC bought a new stake in shares of PROCEPT BioRobotics during the 1st quarter valued at $42,000. Finally, Lazard Asset Management LLC raised its stake in shares of PROCEPT BioRobotics by 90.7% during the 2nd quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock valued at $98,000 after purchasing an additional 810 shares during the period. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Price Performance

NASDAQ:PRCT opened at $21.25 on Thursday. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -10.95 and a beta of 0.89. PROCEPT BioRobotics Corporation has a 52-week low of $16.67 and a 52-week high of $42.71. The stock has a fifty day moving average of $21.29 and a 200 day moving average of $24.56. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). The business had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.PROCEPT BioRobotics’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.35) earnings per share. On average, research analysts expect that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current fiscal year.

Insider Activity

In other PROCEPT BioRobotics news, CEO Larry L. Wood acquired 23,900 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was bought at an average price of $20.85 per share, with a total value of $498,315.00. Following the completion of the acquisition, the chief executive officer owned 23,900 shares of the company’s stock, valued at $498,315. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders sold 1,000 shares of company stock worth $28,480. Company insiders own 4.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PRCT. William Blair cut PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Jefferies Financial Group reiterated a “hold” rating and set a $20.00 price target on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Wells Fargo & Company downgraded shares of PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price target on the stock. in a report on Wednesday, August 5th. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Leerink Partners cut shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $31.00 to $29.00 in a research note on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, PROCEPT BioRobotics presently has a consensus rating of “Hold” and an average price target of $28.00.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: CEO Larry Wood purchased 23,900 shares at an average price of $20.85, investing approximately $498,315. The open-market purchase may support investor confidence by signaling that management believes the stock is undervalued. SEC Form 4 filing
• Neutral Sentiment: Several firms reiterated that investors who purchased PRCT shares between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek lead-plaintiff status. These announcements are primarily procedural, but their frequency keeps legal uncertainty in focus. Securities class action deadline notice
• Negative Sentiment: The complaints allege that PROCEPT and certain executives misrepresented demand for its robotic prostate-treatment systems, including repeated underperformance in handpiece sales and procedure activity. The allegations also point to excess customer inventory allegedly created by late-quarter bulk discounts, potentially making reported revenue and growth appear stronger than underlying demand. Hagens Berman class action announcement
• Negative Sentiment: The litigation follows an approximately 18% share-price decline and could increase legal expenses, reputational risk, and scrutiny of PROCEPT’s sales strategy. The concerns are particularly significant because the company remains unprofitable and recently reported a quarterly loss that narrowly exceeded analyst expectations, despite revenue growth. Robbins Geller class action announcement

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.